Analysts See $-2.99 EPS for GW Pharmaceuticals plc (GWPH); Partner Investment Management LP Has Upped Its Davita (DVA) Holding

DaVita Inc. (NYSE:DVA) Logo

Analysts expect GW Pharmaceuticals plc (NASDAQ:GWPH) to report $-2.99 EPS on February, 4.They anticipate $0.56 EPS change or 23.05% from last quarter’s $-2.43 EPS. After having $-2.76 EPS previously, GW Pharmaceuticals plc’s analysts see 8.33% EPS growth. The stock increased 1.81% or $2.13 during the last trading session, reaching $119.54. About 595,187 shares traded or 17.79% up from the average. GW Pharmaceuticals plc (NASDAQ:GWPH) has declined 1.75% since January 10, 2018 and is downtrending. It has underperformed by 1.75% the SP500. Some Historical GWPH News: 19/04/2018 – GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 – SEC FILING; 19/04/2018 – GW Pharmaceuticals and U.S; 19/04/2018 – GW PHARMACEUTICALS PLC – PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018; 27/04/2018 – INSYS

... read more at: